Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

As reported by Share Market Today

Biocon jumped nearly 3% in Monday's trade after the company's Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Share Market Today ↗

Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.

INDIAN Global Market: SoftBank launches $10 billion bonds to fund OpenAI investment Markets-Economic Times
INDIAN Warren Buffett once called derivatives time bombs, then bet $40 billion on them. What this says about the legendary investor Markets-Economic Times
INDIAN OFSS shares crack 7%; what's spooking Nifty IT's best-performing stock? Share Market Today
INDIAN PIGL receives solar PV power projects aggregating 24760 KWp Share Market Today
INDIAN Welspun Corp's associate company bags Rs 2,000-cr contract from Aramco Share Market Today
INDIAN NSE IPO subscribed 2.64 times so far on final day; retail lags, NIIs lead Share Market Today
INDIAN Nifty Auto looks set to snap a 5-month winning streak - Should you buy the dip in auto, auto ancillary stocks? mint - markets
GLOBAL Contango Silver & Gold: 2027 Could Change The Valuation Fast (NYSE:CTGO) seekingalpha.com

Biocon spurts 3% as Pertuzumab drug moves closer to marketing nod in Europe

More from Market Samachar